ClinicalTrials.Veeva

Menu
A

Acevedo Clinical Research Associates | Miami, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lubiprostone
Amlitelimab
PF-06882961
PF-05221304
PF-06865571
MK-1654
INCB059872

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 29 total trials

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo (HYDRO)

This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody re...

Enrolling
Dermatitis Atopic
Drug: Amlitelimab
Biological: Tdap vaccine

The purpose of this clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune s...

Active, not recruiting
Shingles
Human
Biological: Selected Vaccine Candidate group (Dose level, Schedule)
Biological: Shingrix - SSB

The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates tar...

Active, not recruiting
COVID-19
SARS-CoV-2 Infection
Biological: BNT162b2 (Omi XBB.1.5)
Biological: BNT162b2 (Omi JN.1)

The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called varian...

Enrolling
COVID-19
SARS-CoV-2 Virus
Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose

The purpose of this study is to evaluate the efficacy, immunogenicity and safety of the 9-valent human papillomavirus (9vHPV) vaccine in men 20 to 45...

Active, not recruiting
Papillomavirus Infections
Biological: 9vHPV Vaccine
Other: Placebo (Saline for Injection)

This is a single group, Phase 2/3, long-term extension study for treatment. The purpose of this study is to characterize the safety and efficacy of a...

Enrolling
Dermatitis Atopic
Drug: Oral corticosteroids
Drug: Amlitelimab

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Trial sponsors

Pfizer logo
BioNTech logo
Merck Sharp & Dohme (MSD) logo
Sanofi logo
Sanofi logo
S
Incyte logo
Lilly logo
Novavax logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems